Mitochondrial Dysfunction in the Aged Heart: Role of Endoplasmic Reticulum Stress

老年心脏线粒体功能障碍:内质网应激的作用

基本信息

项目摘要

Myocardial injury is increased during ischemia and reperfusion in the aged heart and accelerates the transition to post-infarction heart failure. Most therapeutic strategies that effectively decrease cardiac injury in younger hearts fail in aged hearts. Aging causes dysfunctional mitochondria that increase cardiac injury from ischemia and reperfusion. Aging impairs the electron transport chain with decreased oxidative phosphorylation and increased production of reactive oxygen species. Thus, it is a critical need to understand the mechanisms by which age-induced metabolic defects lead to increased injury. We found that endoplasmic reticulum (ER) stress increases during aging. We showed that treatment of aged mice with intervention to decrease ER stress markedly improved mitochondrial function in aged hearts. Following the improvement in baseline mitochondrial function, cardiac injury from a subsequent episode of ischemia and reperfusion was markedly reduced. Complex I is a rate limiting step in the electron transport chain. We found that key protein subunits of complex I are decreased by aging. Activity of the MITO localized protease calpain is increased during aging. We hypothesize that ER stress activates mitochondria-localized calpain causing depletion of subunits of complex I and impairment of complex I function leading to age-induced mitochondrial dysfunction. Aim 1 studies the mechanism of the ER stress mediated injury to complex I via activation of mitochondrial calpain. Our ongoing work showed that chronic metformin treatment reduced ER stress with improved mitochondrial function in aged hearts. AMP protein kinase (AMPK) and mechanistic target of rapamycin (mTOR) are key effectors that respond to metabolic and cell stress. mTORC1 signaling regulates protein synthesis and is linked to ER stress. mTORC2 regulates cell growth and insulin signaling. We found evidence of increased mTORC1 activation in the aged heart with downregulation of mTORC1 following metformin therapy. We hypothesize that metformin decreases ER stress via AMPK-mediated downregulation of mTORC1. The resulting dysfunctional mitochondria need be removed by mitophagy, which is decreased in the aged heart. AMPK and mTOR modulate mitophagy. In initial work, we found that metformin treatment in the aged heart activates mitophagy through AMPK signaling. Metformin treatment thus has the potential to both decrease ER stress mediated direct injury to mitochondria via calpain activation and to facilitate the removal of dysfunctional mitochondria in aged hearts. Aim 2 studies the mechanisms of the downregulation of ER stress by metformin treatment via modulation of mTORC1 and mTORC2 signaling that impacts the ER stress response gene program with the potential enhancement of mitophagy. Age-induced mitochondrial dysfunction increases the susceptibility of the aged heart to injury from subsequent ischemia and reperfusion. We hypothesize that restoration of mitochondrial function with chronic metformin feeding will decrease cardiac injury in the aged hearts. The contribution of restored mitochondrial function in the aged heart to decrease injury from subsequent ischemia and reperfusion is studied in Aim 3. This proposal advances our understanding of the mechanisms of ER stress-mediated mitochondrial dysfunction during aging in the heart and provides guidance to develop clinically relevant approaches to decrease cardiac injury by improving mitochondrial function in aged hearts.
Myocardial injury is increased during ischemia and reperfusion in the aged heart and accelerates the transition to post-infarction heart failure. Most therapeutic strategies that effectively decrease cardiac injury in younger hearts fail in aged hearts. Aging causes dysfunctional mitochondria that increase cardiac injury from ischemia and reperfusion. Aging impairs the electron transport chain with decreased oxidative phosphorylation and increased production of reactive oxygen species. Thus, it is a critical need to understand the mechanisms by which age-induced metabolic defects lead to increased injury. We found that endoplasmic reticulum (ER) stress increases during aging. We showed that treatment of aged mice with intervention to decrease ER stress markedly improved mitochondrial function in aged hearts. Following the improvement in baseline mitochondrial function, cardiac injury from a subsequent episode of ischemia and reperfusion was markedly reduced. Complex I is a rate limiting step in the electron transport chain. We found that key protein subunits of complex I are decreased by aging. Activity of the MITO localized protease calpain is increased during aging. We hypothesize that ER stress activates mitochondria-localized calpain causing depletion of subunits of complex I and impairment of complex I function leading to age-induced mitochondrial dysfunction. Aim 1 studies the mechanism of the ER stress mediated injury to complex I via activation of mitochondrial calpain. Our ongoing work showed that chronic metformin treatment reduced ER stress with improved mitochondrial function in aged hearts. AMP protein kinase (AMPK) and mechanistic target of rapamycin (mTOR) are key effectors that respond to metabolic and cell stress. mTORC1 signaling regulates protein synthesis and is linked to ER stress. mTORC2 regulates cell growth and insulin signaling. We found evidence of increased mTORC1 activation in the aged heart with downregulation of mTORC1 following metformin therapy. We hypothesize that metformin decreases ER stress via AMPK-mediated downregulation of mTORC1. The resulting dysfunctional mitochondria need be removed by mitophagy, which is decreased in the aged heart. AMPK and mTOR modulate mitophagy. In initial work, we found that metformin treatment in the aged heart activates mitophagy through AMPK signaling. Metformin treatment thus has the potential to both decrease ER stress mediated direct injury to mitochondria via calpain activation and to facilitate the removal of dysfunctional mitochondria in aged hearts. Aim 2 studies the mechanisms of the downregulation of ER stress by metformin treatment via modulation of mTORC1 and mTORC2 signaling that impacts the ER stress response gene program with the potential enhancement of mitophagy. Age-induced mitochondrial dysfunction increases the susceptibility of the aged heart to injury from subsequent ischemia and reperfusion. We hypothesize that restoration of mitochondrial function with chronic metformin feeding will decrease cardiac injury in the aged hearts. The contribution of restored mitochondrial function in the aged heart to decrease injury from subsequent ischemia and reperfusion is studied in Aim 3. This proposal advances our understanding of the mechanisms of ER stress-mediated mitochondrial dysfunction during aging in the heart and provides guidance to develop clinically relevant approaches to decrease cardiac injury by improving mitochondrial function in aged hearts.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edward J Lesnefsky其他文献

Edward J Lesnefsky的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edward J Lesnefsky', 18)}}的其他基金

Metformin Therapy for Ischemic Insult and Reperfusion Injury in Aging
二甲双胍治疗衰老缺血性损伤和再灌注损伤
  • 批准号:
    10846164
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Metformin Therapy for Ischemic Insult and Reperfusion Injury in Aging
二甲双胍治疗衰老缺血性损伤和再灌注损伤
  • 批准号:
    10298194
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Metformin Therapy for Ischemic Insult and Reperfusion Injury in Aging
二甲双胍治疗衰老缺血性损伤和再灌注损伤
  • 批准号:
    10475290
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Reduction of cardiac injury by targeting damaged mitochondria during reperfusion
通过针对再灌注期间受损的线粒体来减少心脏损伤
  • 批准号:
    8457978
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Reduction of cardiac injury by targeting damaged mitochondria during reperfusion
通过针对再灌注期间受损的线粒体来减少心脏损伤
  • 批准号:
    8795682
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Reduction of cardiac injury by targeting damaged mitochondria during reperfusion
通过针对再灌注期间受损的线粒体来减少心脏损伤
  • 批准号:
    8698292
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Reduction of cardiac injury by targeting damaged mitochondria during reperfusion
通过针对再灌注期间受损的线粒体来减少心脏损伤
  • 批准号:
    8333547
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Mitochondrial Dysfunction in the Aged Heart: Role of Endoplasmic Reticulum Stress
老年心脏线粒体功能障碍:内质网应激的作用
  • 批准号:
    10254899
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Myocardial Infarction in the Aging Heart: Ischemia-Damaged Mitochondria, Reticulum Stress and the Transition to Heart Failure
衰老心脏中的心肌梗死:缺血损伤的线粒体、网状应激和向心力衰竭的转变
  • 批准号:
    9239811
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
COMPLEX III AUGMENTS OXIDANTS DAMAGE IN ISCHEMIC AGED HEART
复合物 III 增强缺血性老年心脏的氧化剂损伤
  • 批准号:
    6783212
  • 财政年份:
    2004
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
  • 批准号:
    BB/W009633/1
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
  • 批准号:
    459043
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
  • 批准号:
    2243045
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
  • 批准号:
    428988
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了